Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Abraxane

Abraxane

Abraxane is a nanoparticle albumin-bound formulation of the cancer medication paclitaxel.
It is used to treat a variety of solid tumors, including non-small cell lung cancer, metastatic breast cancer, and advanced pancreatic cancer.
PubCompare.ai can help optimize your Abraxane research by enhancing reproducibility and accuracy.
Its AI-driven platform allows you to easily locate protocols from literature, pre-prings, and patents, while comparing them to identify the best approoches.
Improve your Abraxane studies with PubCompare.ai's powerful analysis tools.

Most cited protocols related to «Abraxane»

1
Modulating Tissue Tension Impacts PC Progression
Cited 17 times
This study interrogates the effect of transient manipulation of tissue tension via ROCK inhibition on PC progression and response to Gem/Abraxane. In vitro organotypic and CDM experiments were performed in independent biological triplicates, with three technical replicates per repeat and per treatment group. For in vivo experiments, numbers of mice used for each model are outlined in corresponding figures and figure legends. In vivo priming started when tumor volume reached 180 mm3 (average size) or 7 × 105 photons/s (average IVIS signal). Mice for which tumor volume or IVIS signal was 10% lower or higher than the average value before enrollment were excluded from analysis.
FLIM-FRET analysis of CDK1 and SRC activity in vitro was conducted in >30 cells per group in three independent biological repeats. In vivo analysis of CDK1 and SRC was performed in 80 cells per mouse, with measurements in three subcellular areas per cell to generate an average value for CDK1 specifically, whereas measurements of lifetime in the whole cell (one value per cell) were performed for analysis of SRC activity.
IHC, SHG, picrosirius red, and GLCM analyses were conducted on three representative FOVs in organotypic matrices and CDMs and in five representative FOVs in subcutaneous xenograft and intrasplenic experiments. Metastatic burden, extravasation, and metastasis morphology in the liver were analyzed in serial sections (five sections per organ with a 100-μm step). Experimental end points for survival experiments were in compliance with Garvan Ethics Committee guidelines (13/17, 14/06, 14/11, and 16/13 protocols).
Vennin C., Chin V.T., Warren S.C., Lucas M.C., Herrmann D., Magenau A., Melenec P., Walters S.N., del Monte-Nieto G., Conway J.R., Nobis M., Allam A.H., McCloy R.A., Currey N., Pinese M., Boulghourjian A., Zaratzian A., Adam A.A., Heu C., Nagrial A.M., Chou A., Steinmann A., Drury A., Froio D., Giry-Laterriere M., Harris N.L., Phan T., Jain R., Weninger W., McGhee E.J., Whan R., Johns A.L., Samra J.S., Chantrill L., Gill A.J., Kohonen-Corish M., Harvey R.P., Biankin A.V., Jeffry Evans T.R., Anderson K.I., Grey S.T., Ormandy C.J., Gallego-Ortega D., Wang Y., Samuel M.S., Sansom O.J., Burgess A., Cox T.R., Morton J.P., Pajic M, & Timpson P. (2017). Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. Science translational medicine, 9(384), eaai8504.
Publication 2017
Abraxane Biopharmaceuticals CDK1 protein, human Cells Disease Progression Ethics Committees Fluorescence Resonance Energy Transfer Liver Mus Neoplasm Metastasis Psychological Inhibition Tissues Transients Xenografting
2
Nanomedicine Combo Inhibits Mammary Tumours
Cited 4 times
E0771 mammary tumours were orthotopically implanted in female SCID mice. The mice were split into treatment groups, time-matched for time after implantation and size-matched for tumour volume at this time (110–111mm3). The mice were treated at this initial size with 5mg/kg DC101 or non-specific IgG on days 0 and 3 by intraperitoneal injection. The mice were simultaneously treated with either 2mg/kg Doxil, with a diameter of ~100nm, or 10mg/kg Abraxane, with a diameter of ~10nm, on days 1–5 by retro-orbital injection. These relative doses are similar to the relative doses for these two nanomedicines in patients. The primary tumours were then measured every 3 days, beginning on day 0, using callipers. Tumour growth was quantified using the time for each to reach double its initial volume.
Chauhan V.P., Stylianopoulos T., Martin J.D., Popović Z., Chen O., Kamoun W.S., Bawendi M.G., Fukumura D, & Jain R.K. (2012). Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nature nanotechnology, 7(6), 383-388.
Publication 2012
Abraxane Animal Mammary Neoplasms DC101 monoclonal antibody Doxil Females Injections, Intraperitoneal Mice, House Neoplasms Ovum Implantation Patients SCID Mice
3
Breast Cancer Cell Line Protocols
Cited 4 times
Details on breast cancer cell lines and culture conditions are presented in the Supplementary material. TRA-8 antibody (mouse IgG1 isotype) was prepared at the University of Alabama at Birmingham [15 (link)]. Doxorubicin was obtained from Polymed Therapeutics (Houston, TX). Paclitaxel was from Sigma Aldrich Chemical Co. (St. Louis, MO). Abraxane was from the University of Alabama at Birmingham Hospital Pharmacy.
Oliver P.G., LoBuglio A.F., Zhou T., Forero A., Kim H., Zinn K.R., Zhai G., Li Y., Lee C.H, & Buchsbaum D.J. (2011). Effect of anti-DR5 and chemotherapy on basal-like breast cancer. Breast cancer research and treatment, 133(2), 417-426.
Publication 2011
Abraxane Doxorubicin IgG1 Immunoglobulin Isotypes Immunoglobulins MCF-7 Cells Mus Paclitaxel Therapeutics TRA-8
4
Peptide-Conjugated Abraxane: In Vitro and In Vivo Evaluation
Cited 4 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2009
Abraxane Biological Assay Cells Cell Survival Culture Media Cytotoxin Heart Heterografts Immunofluorescence Mice, Nude Mus N-end cysteine peptide tumor-homing peptide Neoplasms Paclitaxel Peptides Tissues
5
Pancreatic Cancer Mouse Models and Therapy
Cited 3 times
Six‐week‐old female and male PdxCre/LSL‐KrasG12D (KC) mice (Hingorani et al, 2003), PdxCre/LSL‐KrasG12D/+/LSL‐Trp53R172H/+ (KPC) mice (Hingorani et al, 2005; Capello et al, 2013), and PdxCre control mice were maintained at Biogem (Ariano Irpino, Avellino, IT). Chronic pancreatitis was induced in 10‐week‐old sex‐matched C57BL/6 mice (Envigo, Correzzana, Italy) as previously described (Neuschwander‐Tetri et al, 2000). Briefly, mice were injected intraperitoneally with 50 μg/kg of caerulein (AnaSpec, Fremont, CA, USA) 6 times over 5 consecutive hours, three times a week for 7 weeks. The severity of acute injury was initially verified by measuring plasma pancreatic α‐amylase using Reflotron tests (Roche, Mannheim, Germany). Pancreatic tissue atrophy and fibrosis were detected by Sirius Red staining at sacrifice.
Three patient‐derived PDAC xenografts (HuPa4, HuPa8, and HuPa11) were engrafted in 6‐ to 8‐week‐old male severe combined immunodeficiency (SCID) mice (Envigo, Correzzana, Italy) by orthotopic intrapancreas transplantation (manuscript in preparation). The PDAC‐PDX models were molecularly and biologically characterized and found to be similar to the original tumor patient. PDAC‐PDX were used within the third passage after their first engraftment.
PDAC‐PDX growth in the pancreas was monitored by abdominal palpation and by magnetic resonance imaging (MRI) using 7‐Tesla BioSpec AVIII system (Bruker Biospin). T2‐weighted high‐resolution sequences were analyzed using ImageJ software to calculate tumor volume (Cesca et al, 2016).
Nab–paclitaxel (Abraxane®, Celgene; 25 mg/kg i.v.) and gemcitabine (Gemcitabina Teva, Teva, 150 mg/kg i.v.) (HDE: 75 and 450 mg/m2, respectively) were given as single treatment or in combination, on days 1 and 8 of each 21‐day cycle for a total of 8 treatments.
Mice were maintained under specific pathogen‐free conditions, housed in isolated vented cages, and handled using aseptic procedures. Procedures involving animals and their care were conducted in conformity with institutional guidelines that comply with national (Lgs 26/2014) and EU directives laws and policies (EEC Council Directive 2010/63), in line with guidelines for the welfare and use of animals in cancer research (Workman et al, 2010). Animal studies were approved by the Mario Negri Institute Animal Care and Use Committee and by Italian Ministry of Health (DM 85/2013‐B and Authorization no. 601/2016‐PR).
Resovi A., Bani M.R., Porcu L., Anastasia A., Minoli L., Allavena P., Cappello P., Novelli F., Scarpa A., Morandi E., Falanga A., Torri V., Taraboletti G., Belotti D, & Giavazzi R. (2018). Soluble stroma‐related biomarkers of pancreatic cancer. EMBO Molecular Medicine, 10(8), e8741.
Full text: Click here
Publication 2018
130-nm albumin-bound paclitaxel Abdomen Abraxane alpha-Amylases Animals Anophthalmia with pulmonary hypoplasia Asepsis Atrophy Ceruletide Fibrosis Gemcitabine Hereditary pancreatitis Heterografts Injuries Males Malignant Neoplasms Mice, House Mice, Inbred C57BL Neoplasms Palpation Pancreas Patients Plasma SCID Mice Specific Pathogen Free Tissues Transplantation Woman

Most recents protocols related to «Abraxane»

1
Rituximab-Loaded ABRAXANE Nanoparticles
Not available on PMC !

Example 1

The particles are synthesized by adding between about 5 mg and about 20 mg of rituximab (or non-specific IgG) to 20 mg of ABRAXANE. Saline is then added to a final volume of 2 ml for a final concentration of 10 mg/ml ABRAXANE, and the mixture is allowed to incubate at room temperature for 30 minutes to allow particle formation. Particles average about 160 nm and are termed “AR160” nanoparticles.

Optionally, the composition is divided into aliquots and frozen at −80° C. Once frozen the aliquots are optionally lyophilized overnight with the Virtis 3L benchtop lyophilizer (SP Scientific, Warmister, PA) with the refrigeration on. A lyophilized preparation is generated.

The dried aliquots are stored at room temperature. These samples are reconstituted in saline at room temperature for 30 minutes, followed by centrifugation for 7 minutes at 2000×g. The resulting sample is then resuspended in the appropriate buffer, as needed.

US11878061B2. Methods for improving the therapeutic index for a chemotherapeutic drug (2024-01-23). Mayo Foundation for Medical Education and Research [US]. Inventors: Svetomir N. Markovic [US], Wendy K. Nevala [US].
Full text: Click here
Patent 2024
Abraxane Albumins Buffers Centrifugation Freezing Rituximab Saline Solution
2
Evaluation of Targeted Nanoparticle Tumor Accumulation
Not available on PMC !

Example 2

Mice were injected via subcutaneous injection with lymphoma cells and tumors allowed to form. Mice received intravenous (IV) injection of equal amounts of alexaflor 750-labeled ABRAXANE (ABX), ABRAXANE coated with non-specific antibodies (AB IgG), or AR160.

Twenty-four hours after IV injection, tumor accumulation of the respective treatments was determined based on a fluorescence threshold. Background was determined based on a region of the mouse without a tumor. FIG. 1 is a graphical representation of background and tumor fluorescence. Table 8 indicates the numerical values for each, including tumor-associated fluorescence (average radiant efficiency from the tumor minus background). Addition of rituximab to the ABRAXANE nanoparticle (AR160) results in a nearly 100% increase in tumor uptake of ABRAXANE.

TABLE 8
Average Radiant Efficiency and Adjusted Tumor-Associated Fluorescence
Tumor-
associated
BackgroundTumorFluorescence
ABX1.5412.090.549
AB IgG1.40051.990.5895
AR1601.5452.6371.092

US11878061B2. Methods for improving the therapeutic index for a chemotherapeutic drug (2024-01-23). Mayo Foundation for Medical Education and Research [US]. Inventors: Svetomir N. Markovic [US], Wendy K. Nevala [US].
Full text: Click here
Patent 2024
Abraxane Antibodies Cells Fluorescence Immunoglobulin G Lymphoma Mus Neoplasms Rituximab Subcutaneous Injections
3
In Vivo Anti-Tumor Efficacy of TPGS-TG and Abraxane
In vivo anti-tumor TPGS-TG assays were performed in MCF-7 tumor-bearing nude mice. When the tumor volume reached approximately 100–120 mm3, mice were randomly assigned to six groups (n = 6): (a) normal saline group (Control); (b) 375 mg/kg TPGS-TG (High TPGS TG); (c) 15 mg/kg Abraxane® (Abraxane); (d) blank TG combined with 15 mg/kg Abraxane® (Blank TG-Abraxane); (e) 375 mg/kg TPGS-TG combined with 15 mg/kg Abraxane® (High TPGS TG-Abraxane); and (f) 187.5 mg/kg TPGS-TG combined with 15 mg/kg Abraxane® (Low TPGS TG-Abraxane). Blank TG and TPGS-TG were administrated twice via intratumoral injection. Concurrently, Abraxane® was administrated by tail vein injection on days 1, 4, 7, 10, and 13. Body weights and tumor sizes were measured every 2 days. On day 14, mice were humanely sacrificed, and tumor tissue and main organs (liver, spleen, lung, and kidney) immediately sectioned and stained with H&E to assess tissue toxicity.
Tang L., Huang K., Jiang W., Fu L., Zhang R., Shen L., Ou Z., Huang Y, & Zhang Z. (2023). Exploration of the inhibition action of TPGS on tumor cells and its combined use with chemotherapy drugs. Drug Delivery, 30(1), 2183830.
Publication 2023
Abraxane Biological Assay Body Weight Kidney Liver Lung Mice, Laboratory Mice, Nude Neoplasms Normal Saline Spleen Tail Tissues tocophersolan Veins
4
Nanoparticle-Mediated Drug Delivery in Cancer Treatment
TPGS was purchased from Haimen Huiju Pharmaceutical Co., Ltd (Haimen, China). DOX was purchased from Dalian Meilun Biotech Co., Ltd (Dalian, China). Abraxane® was purchased from Shiyao Group Ouyi Pharmaceutical Co., Ltd (Shijiazhuang, China). Chlorpromazine hydrochloride and verapamil were purchased from Aladdin Scientific Inc. (Shanghai, China). Dulbecco’s modified Eagle’s Medium (DMEM), phosphate buffered saline (PBS), Roswell Park Memorial Institute-1640 (RPMI-1640), trypsin, and penicillin-streptomycin solution were purchased from Jinuo Biotech Co., Ltd (Hangzhou, China). Fetal bovine serum (FBS) was purchased from Gibco (Grand Island, NY, USA). A cytochrome C primary antibody was purchased from ABclonal Technology Co., Ltd (Wuhan, China). A β-actin antibody was purchased from Santa Cruz Biotechnology Co., Ltd (USA). Hematoxylin and eosin (H&E) were obtained from Guge Biotechnology Co., Ltd (Wuhan, China). Polyethylene-polypropylene glycol 407 (PL407) and polyethylene-polypropylene glycol 188 (PL188) were purchased from BASF Co., Ltd (Germany). All other reagents and chemicals were analytical grade.
Tang L., Huang K., Jiang W., Fu L., Zhang R., Shen L., Ou Z., Huang Y, & Zhang Z. (2023). Exploration of the inhibition action of TPGS on tumor cells and its combined use with chemotherapy drugs. Drug Delivery, 30(1), 2183830.
Publication 2023
Abraxane Actins Cytochromes c Eagle Eosin Fetal Bovine Serum Hematoxylin Hydrochloride, Chlorpromazine Immunoglobulins Penicillins Pharmaceutical Preparations Phosphates Poloxalene Saline Solution Streptomycin tocophersolan Trypsin Verapamil
5
PIPAC Treatment for Peritoneal Metastases
The choice of 10.5 mg/m2 cisplatin dose has been based on the result of the recent phase I escalation dose of cisplatin and doxorubicin association administered IP by PIPAC.8 (link) The MTD dose in the phase I of IP nab-paclitaxel administration by catheterism was 140 mg/m2,32 (link) we are expecting MTD at a lower dose for this phase I as PIPAC has an enhanced activity and penetration than conventional IP treatment. Cisplatin 10.5 mg/m2 body surface in 150 mL NaCl 0,9% (concentration of 1 mg/mL) and nab-paclitaxel (Abraxane) in 150 mL NaCl 0,9% at escalating doses will be applied sequentially through a nebuliser (Capnopen, Capnomed, Villigendorf, Germany) to a high-pressure injector (Accutron HP-D Injecteur, Medtron AG) with a flow rate of 0.6–0.7 mL/s and a median droplet size of 11 (3-15) μm at ambient temperature and at a maximal upstream pressure of 300 psi intraperitoneally. Treatment will be maintained for 30 min after administration at a pressure of 12 mm Hg.
PIPAC will be performed only by gynaecological or gastrointestinal surgeon who has already completed a special training and will be repeated q4–6 week’s intervals for a total of three courses procedure. The length of stay in hospital for the PIPAC procedure is about 4 days. PIPAC procedure will be performed as follow.18 (link)
Lang N., Diciola A., Labidi-Galy I., Ris F., Di Marco M., Mach N., Petignat P., Toso C., Undurraga M, & Hubner M. (2023). Nab-PIPAC: a phase IB study protocol of intraperitoneal cisplatin and nab-paclitaxel administered by pressurised intraperitoneal aerosol chemotherapy (PIPAC) in the treatment of advanced malignancies confined to the peritoneal cavity. BMJ Open, 13(1), e067691.
Publication 2023
130-nm albumin-bound paclitaxel Abraxane Aftercare Cisplatin Doxorubicin Human Body Nebulizers Pressure Sodium Chloride Surgeons

Top products related to «Abraxane»

1
Gemzar by Eli Lilly
Sourced in United States, Japan
Gemzar is a laboratory equipment product manufactured by Eli Lilly. It is a device designed for specific scientific applications. The core function of Gemzar is to facilitate research and analysis, but a detailed description cannot be provided while maintaining an unbiased and factual approach.
2
Gemcitabine by Eli Lilly
Sourced in United States, Japan, France, Germany, United Kingdom, Spain, Canada, Australia
Gemcitabine is a synthetic nucleoside analog used as a laboratory reagent. It functions as an antimetabolite, inhibiting DNA synthesis and cell division.
3
Doxil by Johnson & Johnson
Sourced in Japan
Doxil is a liposomal formulation of the chemotherapeutic agent doxorubicin. It is used for the treatment of certain types of cancer.
4
4 dimethylaminopyridine dmap by Merck Group
Sourced in United States, Germany, China, Poland
4-Dimethylaminopyridine (DMAP) is a laboratory reagent commonly used as a nucleophilic catalyst. It is a white crystalline solid that exhibits basic properties. DMAP is known for its ability to facilitate various organic reactions, such as esterification and acylation, by activating carbonyl groups.
5
Pegylated liposomal doxorubicin by Johnson & Johnson
Sourced in Belgium
Pegylated liposomal doxorubicin is a type of drug delivery system. It consists of the chemotherapeutic agent doxorubicin encapsulated within a liposomal formulation that has been modified with polyethylene glycol (PEG) to prolong its circulation time in the body.
6
Human albumin by Cell Signaling Technology
Human albumin is a laboratory product derived from human serum. It is a naturally occurring protein that plays a critical role in maintaining the oncotic pressure of blood plasma.
7
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
8
Guava 8ht by Merck Group
Sourced in United Kingdom, United States
The Guava 8HT is a compact and user-friendly flow cytometer designed for high-throughput cell analysis. It features an 8-color detection system and is capable of analyzing up to 96 samples in a single run. The Guava 8HT provides reliable and efficient data acquisition for a wide range of applications.
9
Dulbecco s modified eagle s medium dmem by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Canada, France, Australia, Japan, India, Spain, Switzerland, Israel, Italy, Belgium, Austria, New Zealand, Brazil, Argentina, Denmark, Ireland, Singapore, Egypt
Dulbecco's modified Eagle's medium (DMEM) is a cell culture medium commonly used for the in vitro cultivation of various cell types. It provides a balanced salt solution, amino acids, vitamins, and other nutrients required for cell growth and maintenance.
10
Docetaxel dtx by LC Laboratories
Sourced in United States
Docetaxel (DTX) is a chemotherapeutic agent used in the treatment of various types of cancer. It is a semi-synthetic taxane derivative that acts as a mitotic inhibitor, disrupting the normal function of microtubules and leading to cell cycle arrest and apoptosis in rapidly dividing cells. Docetaxel is commonly used in the management of breast, lung, prostate, and other solid tumors.

More about "Abraxane"

Abraxane is a nanoparticle formulation of the anticancer drug paclitaxel, bound to human albumin.
It is used to treat various solid tumors, including non-small cell lung cancer, metastatic breast cancer, and advanced pancreatic cancer.
PubCompare.ai is a powerful AI-driven platform that can help optimize your Abraxane research by enhancing reproducibility and accuracy.
The platform allows you to easily locate and compare protocols from literature, pre-prints, and patents, enabling you to identify the best approaches for your Abraxane studies.
This can be particularly useful when exploring combination therapies, such as Abraxane with Gemzar (gemcitabine) or Doxil (pegylated liposomal doxorubicin).
PubCompare.ai's analysis tools can also help you improve the quality and efficiency of your Abraxane experiments.
For example, you can use the platform to compare different cell culture conditions, such as the use of Dulbecco's modified Eagle's medium (DMEM) or FBS (fetal bovine serum), or to evaluate the impact of 4-dimethylaminopyridine (DMAP) on Abraxane formulations.
By leveraging the insights and capabilities of PubCompare.ai, you can enhance the reproducibility and accuracy of your Abraxane research, leading to more robust and reliable results.
Improve your Abraxane studies and stay ahead of the curve with PubCompare.ai's cutting-edge analysis tools.